---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-001504"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T12:55:25.999892+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience 2025 revenue $86.6M, net loss $56.7M incl $48M goodwill impairment; permanent CFO appointed

## Summary
- Q4 revenue $23.7M (down from $24.6M YoY); gross margin 59.7% (up from 57.1%).
- Full-year net loss $56.7M driven by $48.0M goodwill impairment in Q1 2025.
- Adjusted EBITDA $8.1M for FY2025 vs $7.2M in FY2024; operating cash flow $6.7M vs $1.4M.
- Interim CFO Mark Frost appointed permanent CFO effective March 12, 2026.
- Introduced FY2026 guidance for revenue growth from new translational science products; no specific figures provided.

## SEC filing metadata
- accession: 0001171843-26-001504
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184326001504/0001171843-26-001504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184326001504/f8k_031226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-001504
- JSON: https://secwatch.observer/filing/0001171843-26-001504.json
- Plain text: https://secwatch.observer/filing/0001171843-26-001504.txt

## Key facts
- Earnings Releases
  HARVARD BIOSCIENCE INC reported financial results for three and twelve months ended December 31, 2025.
  - Period: three and twelve months ended December 31, 2025
  - Result: reported results
  source text: On March 12, 2026, Harvard Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the three and twelve months ended December 31, 2025, and the details of a related conference call to be held at 8:00 AM ET on March 12, 2026. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184326001504/0001171843-26-001504-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.